Loading…
French clinical-stage biotech developing a nanoparticle injected into tumors to enhance the effect of radiotherapy.
French clinical-stage biotech developing a nanoparticle injected into tumors to enhance the effect of radiotherapy.
Has no commercial revenue to speak of: income comes from licence payments, notably the 2019 deal with Janssen, Johnson & Johnson's pharmaceutical arm, which gave it a partner outside the US. Hensify has a European CE mark for soft-tissue sarcoma but is mostly a development-stage product.
In one line: A radiotherapy-enhancement biotech, unlike any single US analogue.
Moat: narrow (IP / patents, regulatory licence). Patented nanoparticle technology with regulatory approval in some markets, but unproven at commercial scale.
Headquarters: Paris, France · Founded: 2003 · Employees: 97
Size Nanobiotix (NANO.PA) is a France Health Care company (Pharmaceuticals: Major) with a market value of $1.54B, the 116th largest of 206 France companies the cockpit tracks. Shares closed at €27.00 on 6 Nov 2026.
Performance Over six months the shares fell 41.5%, against -2.8% for the median peer and -0.4% for the France market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue fell 76.9% over the last twelve months (peer median +6.2%); the operating margin is -392.0% (peer median 10.2%).
Valuation It trades at 164.1× enterprise value to sales against a peer median of 3.5× (most expensive of 19).
Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €8.36M | €29.6M | -€11.6M | €30.1M | €0 |
| Revenue growth | — | — | -139% | — | — |
| Gross profit | n/a | n/a | n/a | n/a | -€1.50M |
| EBITDA | -€31.2M | -€12.2M | -€71.1M | -€28.9M | -€49.0M |
| Net income | -€52.9M | -€24.0M | -€68.1M | -€39.7M | -€57.0M |
| Free cash flow | -€40.2M | -€35.5M | -€21.4M | -€19.8M | -€38.1M |
| Capital expenditure | €1.01M | €546,000 | €848,000 | €337,000 | €93,000 |
| Total debt | n/a | €95.3M | €50.9M | €50.6M | €53.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Nanobiotix NANO.PA | $1.54B | -42% | -77% | -392% | 164.1× | n/a |
| Siemens Healthineers SHL.DE | $55.9B | +31% | -1% | 15% | 2.7× | 9.0% |
| Boston Scientific BSX | $62.0B | -21% | +9% | 21% | 3.5× | 5.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NANO.PA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +31.6% | +1.6% | 2nd highest of 21 |
| 6-month return | -41.5% | -2.8% | 4th lowest of 21 |
| Distance from 52-week high | -43.4% | -19.0% | 5th lowest of 21 |
| Revenue growth (TTM) | -76.9% | +6.2% | lowest of 19 |
| Operating margin | -392.0% | 10.2% | 2nd lowest of 19 |
| EV / Sales | 164.1× | 3.5× | most expensive of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Nanobiotix NANO.PA | France | $1.54B | -42% | -77% | -392% | 164.1× | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.55B | +53% | -6% | -19% | 13.6× | 49.9% | -13.2% |
| Indegene INDGN.NS | India | $1.56B | +15% | +36% | 12% | 3.3× | 29.6% | +29.4% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.56B | -5% | +4% | 9% | 1.5× | -5.8% | +1.9% |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.53B | -17% | +2% | -2% | 15.1× | n/a | n/a |
| Ultragenyx Pharmaceutical RARE | United States | $1.52B | +22% | +16% | -64% | 3.3× | n/a | n/a |
| Corona Remedies CORONA.NS | India | $1.58B | +40% | +17% | 18% | 9.6× | 37.6% | +16.6% |
| Xiamen Kingdomway 002626.SZ | China | $1.58B | +15% | -3% | 11% | 3.4× | n/a | n/a |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.58B | -4% | +16% | 9% | 1.7× | n/a | n/a |
| LigaChem Biosciences 141080.KS | South Korea | $1.59B | -68% | -33% | -208% | 18.4× | n/a | n/a |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.49B | -17% | +1% | 19% | 2.3× | -8.5% | +4.6% |
| ABL Bio 298380.KS | South Korea | $1.49B | -73% | -64% | -251% | 55.7× | n/a | n/a |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.60B | -5% | +16% | 24% | 3.7× | -4.1% | +0.2% |
| Eton Pharmaceuticals ETON | United States | $1.61B | +236% | +81% | 16% | 15.3× | 39.6% | +359.6% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.62B | -4% | +7% | 17% | 2.2× | -4.5% | +6.8% |
| Damora Therapeutics DMRA | United States | $1.46B | -2% | n/a | n/a | n/a | n/a | n/a |
| Marksans Pharma MARKSANS.NS | India | $1.45B | +50% | +24% | 20% | 3.9× | 31.6% | +16.6% |
| Pacira Biosciences PCRX | United States | $1.45B | +57% | +6% | 4% | 2.2× | 14.9% | +11.1% |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.45B | -48% | n/a | n/a | n/a | n/a | n/a |
| Ocular Therapeutix OCUL | United States | $1.45B | -32% | -8% | -603% | 17.9× | n/a | n/a |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +5% | +15% | 35% | 2.2× | -15.1% | +13.5% |